GlassScriptPhysician profile
Apolinario B Mateo
NPI 1114964145
$2,103.94
in general payments reported to CMS, 2019-2025
16 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2021: $375 · 2022: $783 · 2024: $382 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $757.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.80 | 2021-2025 | Wainua |
| Viiv Healthcare Company | $272.04 | 2022 | |
| Mannkind Corporation | $210.40 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $173.81 | 2019 | |
| Alexion Pharmaceuticals, INC. | $129.90 | 2025 | Ultomiris |
| Incyte Corporation | $125.24 | 2024 | Opzelura |
| Exeltis, USA INC. | $123.25 | 2024 | Slynd |
| Csl Behring | $111.01 | 2024 | Kcentra |
| Gilead Sciences, INC. | $100.00 | 2022 | |
| Ucb, INC. | $89.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $35.86 | 2025 | Uzedy |
| Glaxosmithkline, LLC. | $31.67 | 2025 | Jemperli |
| Neurocrine Biosciences, INC. | $26.47 | 2025 | |
| Azurity Pharmaceuticals, INC. | $23.16 | 2025 | Danziten |
| Evofem Biosciences, INC. | $22.77 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Taiho Oncology, INC. | $18.57 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Apolinario Mateo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.